Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Vaccine|July 30, 2021
COVID-19 vaccine capacity: Challenges and mitigation - The DCVMN perspectiveBenoit Hayman, Rajinder Suri, Sai D Prasad
Frontiers in Immunology|December 26, 2022
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)Raju Sunagar, Sai D Prasad, Raches Ella, et al.
Vaccine|May 16, 2022
Vaccines: New challenges, new paradigms, new opportunities: Report of the 22nd DCVMN Annual General MeetingRajinder Kumar Suri, Benoit Hayman, Sai D Prasad, et al.
Vaccine|May 8, 2014
Development and preclinical testing of HNVAC, a cell culture-based H1N1 pandemic influenza vaccine from IndiaNagendra R Hegde, Deepak Kumar, P Panduranga Rao, et al.
Microorganisms|August 27, 2021
Evidence of Extended Thermo-Stability of Typhoid Polysaccharide Conjugate VaccinesFang Gao, Kay Lockyer, Alastair Logan, et al.
Human Mutation|September 15, 2004
GJB2: the spectrum of deafness-causing allele variants and their phenotypeHela Azaiez, G Parker Chamberlin, Stephanie M Fischer, et al.
Vaccine|July 1, 2020
Emerging manufacturers engagements in the COVID -19 vaccine research, development and supplySonia Pagliusi, Stephen Jarrett, Benoit Hayman, et al.
Vaccine|April 2, 2025
A double-blind, randomised phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot to lot consistency of single component oral cholera vaccine BBV131 (Hillchol®) in comparison to Shanchol™Krishna Mohan Vadrevu, Abhishek Chavan, Amit Chawla, et al.
Human Vaccines & Immunotherapeutics|November 15, 2023
Phase III randomized clinical studies to evaluate the immunogenicity, lot-to-lot consistency, and safety of ROTAVAC® liquid formulations (ROTAVAC 5C & 5D) and non-inferiority comparisons with licensed ROTAVAC® (frozen formulation) in healthy infantsKrishna Kumari P, Siddharth Reddy Chiteti, Vinay K Aileni, et al.
Iscience|March 16, 2021
Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluationBrunda Ganneru, Harsh Jogdand, Vijaya Kumar Daram, et al.
Pageof 2